Passive immunotherapy with plasma derived from convalescent patients recovering from SARS-CoV-2 infection can be a promising approach in the treatment of COVID-19 patients. It is important that blood establishments are ready to satisfy requests for immune plasma by defining the requirements applicable to plasma donors and the standards for preparation, qualification, storage, distribution, and control of product use. This Position paper aims to give recommendations on the biological characteristics of a plasma preparation from convalescent donors and to support the evaluation of this therapeutic approach in more rigorous investigations. 



Patrizia Accorsi - Department of Haematology, Transfusion Medicine and Biotechnologies, Ospedale Civile, Pescara

Pierluigi Berti - Immunohaematology and Transfusion Medicine, “Umberto Parini” Hospital, Aosta

Vincenzo de Angelis - Transfusion Medicine Department, Azienda Sanitaria Universitaria "Friuli Centrale", Udine

Giustina De Silvestro - Blood Transfusion Service, University Hospital of Padua, Padua

Luca Mascaretti - Transfusion Medicine Department, Azienda Sanitaria Universitaria “Giuliano Isontina”, Trieste

Angelo Ostuni - on behalf of the Italian Society for Transfusion Medicine and Immunohaematology (SIMTI) and the Italian Society for Haemapheresis and Cell Manipulation (SIdEM); Transfusional Medicine Unit, University-Hospital Policlinico, Bari, Italy

  • Abstract viewed - 365 times
  • PDF downloaded - 39 times